N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: De IR Parker, et al.

Serial No. 09/782,855

Filed: February 14, 2001

For: Estrogen Receptor Modulators

Art Unit: 1625

Examiner: Covington, R.

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By A

Date 12-4-07

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc. 07/31/2001

RELATED APPLICATION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

U. S. SERIAL NUMBER	FILING DATE	MERCK CASE
upon which the instant application relies for an earlier filing date t	under 35 II S C 120. Therefore	nursuant to
·		
37 C.F.R. 1.98(d), copies of these references are not enclosed h	erewith. If this is inconvenient, a	additional
copies will be submitted upon request.		
5. In accordance with 37 C.F.R. 1.97, (check one)		
the attached information is filed within three months of the fil	ing date of the captioned case.	
the attached information is filed more than three months after merits.	er the filing date but prior to a firs	t Official Action on the
the attached information is being filed more than three month Action on the merits, but before Final Action or Notice of Allo to charge Deposit Account No. 13-2755 for the fee required	wance. The enclosed authoriza	receipt of the first Offic tion is therefore given
the undersigned certifies that each item of information contain a communication from a foreign patent office in a counterpote to the filing of this Statement.	ined in this Information Disclosu part foreign application not more	re Statement was cited than three months pri
the undersigned certifies that no item of information contains a communication from a foreign patent office in a counterparsigning the certification after making reasonable inquiry, was 1.56(c) more than three months prior to the filing of the state	rt foreign application or, to the kr s known to any individual designa	nowledge of the persor
	Respectfully submitted,	
	SUCCES M. Wallinger	llinges_
		olicant(s)
	Reg. No. 45,194	
	MERCK & CO., INC.	

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc. 07/31/2001

Date: December 4, 2001

Rahway, N.J. 07065-0907

Patent Dept., RY60-30

P.O. Box 2000

(732)594- 1077